



GlaxoSmithKline Pharmaceuticals Ltd.
GSK House,
Dr. Annie Besant Road, Worli,
Mumbai - 400 030

Tel No: +91 22 2495 9595
Fax No: +91 22 2495 9494
Web: www.gsk-india.com
Email: askus@gsk.com

10th February 2016

TO,
BSE LIMITED
PHIROZE JEEJEEBHOY TOWERS
DALAL STREET
MUMBAI - 400001

TO,
NATIONAL STOCK EXCHANGE OF INDIA LIMITED
EXCHANGE PLAZA LISTING DEPT
PLOT NO. C/1 G BLOCK BANDRA-KURLA
COMPLEX
BANDRA (E)
MUMBAI - 400051

Dear Sir,

Unaudited Standalone financial results for the quarter and nine months ended 31st December 2015

Pursuant to Clause 33 read with Clause 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the Un-audited Standalone Financial Results and Limited Review Report for the quarter and nine months ended 31st December 2015. Also find enclosed a copy of the press release in this regard.

The Meeting of the Board of Directors of the Company commenced at 12.00 p.m. and concluded at 3.30 p.m.

This is for your information and record.

Yours faithfully
GlaxoSmithKline Pharmaceuticals Limited

Ajay Nadkarni
General Manager - Administration
& Company Secretary

Encl:

GlaxoSmithKline Pharmaceuticals Limited

Registered Office: Dr. Annie Besant Road, Mumbai - 400 030

STATEMENT OF STANDALONE UNAUDITED RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2015


	(Rs. lakhs)		
	3 months ended 31.12.2015	Unaudited 9 months ended 31.12.2015	Corresponding 3 months ended 31.12.2014
Total Income from Operations (net)	73559	206399	65086
Profit from ordinary activities before tax	12493	41455	10052
Net Profit from ordinary activities	7990	26923	4530
Paid-up Equity Share Capital (Face value per share Rs. 10)	8470	8470	8470
Reserves excluding Revaluation Reserves as shown in the Balance Sheet of previous year) *	-	-	-
Earnings Per Share (EPS) (of Rs. 10 each) (not annualised)			
Basic and diluted EPS (Rs.)	9.4	31.8	5.3

* Reserves (excluding Revaluation Reserves as shown in the Balance Sheet of previous year) - Rs.176696 lakhs as on 31st March, 2015.

Notes:

1. The above is an extract of the detailed format of the Financial Results for the quarter and nine months ended 31st December, 2015 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the said Financial Results are available on the website of the Company at www.gsk-india.com and on the website of Stock Exchanges at www.nseindia.com and www.bseindia.com.
2. As the Company's accounting year has been changed from January - December to April - March, the financial results for the current period are for nine months ended 31st December, 2015.
3. The above Results were reviewed by the Audit Committee and were thereafter approved by the Board of Directors at their respective meetings held on 10th February, 2016.
4. The statutory auditors have carried out a limited review of the standalone results for the quarter ended 31st December, 2015.
5. The figures for 2014 have been regrouped wherever necessary to facilitate comparison.

By Order of the Board


Annaswamy Vaidheesh
Managing Director
DIN: 1444303

10th February, 2016

Price Waterhouse & Co Bangalore LLP

Chartered Accountants

The Board of Directors
GlaxoSmithKline Pharmaceuticals Limited
Dr. Annie Besant Road
Mumbai – 400030

1. We have reviewed the statement of unaudited financial results of GlaxoSmithKline Pharmaceuticals Limited (the "Company") for the quarter ended December 31, 2015 which are included in the accompanying standalone Unaudited Results for the quarter and nine months ended December 31, 2015 (the "Statement"). The Statement has been prepared by the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the "Listing Regulations, 2015"), which has been initialled by us for identification purposes. The Statement is the responsibility of the Company's management and has been approved by the Board of Directors. Our responsibility is to issue a report on the Statement based on our review.
2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement.
3. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the Statement has not been prepared in all material respects in accordance with the applicable Accounting Standards prescribed under Section 133 of the Companies Act, 2013 read with Rule 7 of the Companies (Accounts) Rules, 2014 and other recognised accounting practices and policies, and has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Price Waterhouse & Co Bangalore LLP
Firm Registration Number: 007567S/ S-200012
Chartered Accountants

Asha Ramanathan

Asha Ramanathan
Partner
Membership Number 202660

Mumbai
February 10, 2016

Price Waterhouse & Co Bangalore LLP, 252, Veer Savarkar Marg, Shivaji Park, Dadar (West)
Mumbai - 400 028
T: +91 (22) 66691500, F: +91 (22) 66547804 / 07

Registered office and Head office: 5th Floor, Tower D, The Millenia, 1 & 2 Murphy Road, Ulsoor, Bangalore - 560 008

Price Waterhouse & Co., Bangalore (a Partnership Firm) converted into Price Waterhouse & Co Bangalore LLP (a Limited Liability Partnership with LLP identity no: LLPINAAC-6284) with effect from, August 25, 2014. Post its conversion to Price Waterhouse & Co Bangalore LLP, its ICAI registration number is 007567S/S-200012 (ICAI registration number before conversion was 007567S)



+Press Release
Mumbai, 10th February 2016

GlaxoSmithKline Pharmaceuticals Limited records 13% Net Sales growth for Q3, FY 2016

GlaxoSmithKline Pharmaceuticals Limited today declared its financial results for the third quarter ended 31st December 2015. Net sales at Rs.729 crores recorded a growth of 13% as compared to the same prior year period. Profit Before Tax (PBT) at Rs. 125 crores and Profit After Tax (PAT) at Rs 80 crores grew by 24% and 76% respectively against the same prior year period.

Commenting on the results, **Vaidheesh Annaswamy, Managing Director, GlaxoSmithKline Pharmaceuticals Limited** said,

"Our financial performance for the quarter highlights a return to Net Sales growth. The quarter includes the vaccine sales arising from the Asset Sales Agreement with Novartis India that concluded at the end of the prior quarter and contributed to 4% of the sales growth.

The cost base in this quarter, as compared to the corresponding prior year quarter, includes an incremental Corporate Social Responsibility cost of 11 Cr as part of our commitment to eliminate Lymphatic Filariasis in India alongside the World Health Organisation (WHO).

Investments at our existing site at Nashik as well as our proposed state of the art manufacturing site at Vemgal, Bangalore, are on track to continue to deliver high quality products to meet the future demands of our Indian patients.

Our PAT growth of 76% also reflects the reduction in exceptional items as compared to the corresponding prior year quarter".

About GlaxoSmithKline Pharmaceuticals Limited

GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of GlaxoSmithKline plc, one of the world's leading research-based pharmaceutical and healthcare companies, committed to improving the quality of human life by enabling people to do more, feel better and live longer. For more information, visit www.gsk-india.com

Media Contacts:

Ransom D'Souza Head, Corporate Communications

Email: ransom.a.dsouza@gsk.com

Tel: +91 22 24959203